Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
about
HDAC8 substrates: Histones and beyondProteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination.Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations.Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemiaGlobal Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia PatientsExpression of S100A8 in leukemic cells predicts poor survival in de novo AML patients.Perspectives of proteomics in acute myeloid leukemia.High correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia.Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation.Proteomic approaches in myeloid leukemia.Epigenomics in hematopoietic transplantation: novel treatment strategies.AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.Proteomic identification of E6AP as a molecular target of tamoxifen in MCF7 cells.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Comparative proteomics in acute myeloid leukemia.5D proteomic approach for the biomarker search in plasma: Acute myeloid leukaemia as a case study.Comparison of protein acetyltransferase action of CRTAase with the prototypes of HAT.
P2860
Q26824122-2DF8EDCF-AF72-4E34-8445-ADF1EA310C6FQ33257982-271A5DF1-C879-47EF-9AA3-319C2E4DB4DFQ33309313-E0E91554-6388-4D65-8836-ABB82642C3ACQ33491557-36DEFC72-4547-4FED-80D1-B49E1F08DE3FQ33555287-E666C188-399D-4599-87C4-1264D5723E10Q33745000-2452CF0E-B9BA-402C-9CD5-2E5965CA1D55Q36668271-C7C47F7E-9EBD-44B5-A886-908F61CC6AB0Q37072874-D6483226-6664-4ACC-9499-ACBBD760393FQ37342223-F1FFD74B-E41A-4407-9C49-F0E3E3CF474DQ37831255-C7B5AB78-1DCA-4E8D-BF90-30204E71FBF8Q37962599-09FBD280-B0EC-406A-8CD0-1F439C5F9D11Q38033116-2A37D980-9F8A-4224-B165-CAEF583573BEQ38161393-8024B620-4027-4F49-860D-7F38406FE561Q39347752-640150BF-78E1-42EC-ACF2-FC128FA0F3E4Q41973082-36CCF15C-9AD9-4E3E-8FB8-46BA83CAFD69Q43121205-BCFA4ACA-C4CD-421D-A168-FC793FFCF5E3Q47101230-C18D2D44-8F09-4C4B-9E52-7C8CE572873EQ55452081-1230FD28-A2BC-4DB7-9A5A-73FC077A89CB
P2860
Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Proteomics of acute myeloid le ...... ational protein modifications.
@ast
Proteomics of acute myeloid le ...... ational protein modifications.
@en
type
label
Proteomics of acute myeloid le ...... ational protein modifications.
@ast
Proteomics of acute myeloid le ...... ational protein modifications.
@en
prefLabel
Proteomics of acute myeloid le ...... ational protein modifications.
@ast
Proteomics of acute myeloid le ...... ational protein modifications.
@en
P2093
P2860
P356
P1433
P1476
Proteomics of acute myeloid le ...... ational protein modifications.
@en
P2093
Bohlander SK
Christopeit M
Trivedi AK
P2860
P2888
P304
P356
10.1038/SJ.ONC.1209689
P407
P577
2006-05-29T00:00:00Z
P5875
P6179
1003168551